Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | Blood Advances |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952925001715 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850187702571368448 |
|---|---|
| author | Rahul Banerjee Alicia Richards Shonali Midha Aimaz Afrough Faiz Anwer Djordje Atanackovic Shebli Atrash Veronika Bachanova Amer M. Beitinjaneh Evguenia Bhurtel Omar Castaneda Puglianini Saurabh Chhabra Kara I. Cicero James A. Davis Binod Dhakal Danai Dima Christopher J. Ferreri Peter A. Forsberg Ciara L. Freeman Megan M. Herr Tania Jain Murali Janakiram Jack Khouri Mehmet H. Kocoglu Anupama Kumar Yuxin Liu Frederick Locke Joseph P. McGuirk Lekha Mikkilineni Omar Nadeem Ricardo D. Parrondo Oren Pasvolsky Lauren C. Peres Sneha Purvey Shahzad Raza Ran Reshef Shambavi Richard Adriana C. Rossi Douglas W. Sborov Leyla Shune Charlotte B. Wagner Saurabh S. Zanwar Surbhi Sidana Krina K. Patel Doris K. Hansen Shaji K. Kumar Yi Lin Thomas G. Martin Peter M. Voorhees Larry D. Anderson, Jr Andrew J. Cowan Gurbakhash Kaur |
| author_facet | Rahul Banerjee Alicia Richards Shonali Midha Aimaz Afrough Faiz Anwer Djordje Atanackovic Shebli Atrash Veronika Bachanova Amer M. Beitinjaneh Evguenia Bhurtel Omar Castaneda Puglianini Saurabh Chhabra Kara I. Cicero James A. Davis Binod Dhakal Danai Dima Christopher J. Ferreri Peter A. Forsberg Ciara L. Freeman Megan M. Herr Tania Jain Murali Janakiram Jack Khouri Mehmet H. Kocoglu Anupama Kumar Yuxin Liu Frederick Locke Joseph P. McGuirk Lekha Mikkilineni Omar Nadeem Ricardo D. Parrondo Oren Pasvolsky Lauren C. Peres Sneha Purvey Shahzad Raza Ran Reshef Shambavi Richard Adriana C. Rossi Douglas W. Sborov Leyla Shune Charlotte B. Wagner Saurabh S. Zanwar Surbhi Sidana Krina K. Patel Doris K. Hansen Shaji K. Kumar Yi Lin Thomas G. Martin Peter M. Voorhees Larry D. Anderson, Jr Andrew J. Cowan Gurbakhash Kaur |
| author_sort | Rahul Banerjee |
| collection | DOAJ |
| format | Article |
| id | doaj-art-7d450b30a9ff4adb90237eb236d2e7bd |
| institution | OA Journals |
| issn | 2473-9529 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Blood Advances |
| spelling | doaj-art-7d450b30a9ff4adb90237eb236d2e7bd2025-08-20T02:16:02ZengElsevierBlood Advances2473-95292025-05-01992336234010.1182/bloodadvances.2025016131Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myelomaRahul Banerjee0Alicia Richards1Shonali Midha2Aimaz Afrough3Faiz Anwer4Djordje Atanackovic5Shebli Atrash6Veronika Bachanova7Amer M. Beitinjaneh8Evguenia Bhurtel9Omar Castaneda Puglianini10Saurabh Chhabra11Kara I. Cicero12James A. Davis13Binod Dhakal14Danai Dima15Christopher J. Ferreri16Peter A. Forsberg17Ciara L. Freeman18Megan M. Herr19Tania Jain20Murali Janakiram21Jack Khouri22Mehmet H. Kocoglu23Anupama Kumar24Yuxin Liu25Frederick Locke26Joseph P. McGuirk27Lekha Mikkilineni28Omar Nadeem29Ricardo D. Parrondo30Oren Pasvolsky31Lauren C. Peres32Sneha Purvey33Shahzad Raza34Ran Reshef35Shambavi Richard36Adriana C. Rossi37Douglas W. Sborov38Leyla Shune39Charlotte B. Wagner40Saurabh S. Zanwar41Surbhi Sidana42Krina K. Patel43Doris K. Hansen44Shaji K. Kumar45Yi Lin46Thomas G. Martin47Peter M. Voorhees48Larry D. Anderson, Jr49Andrew J. Cowan50Gurbakhash Kaur51Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA; Correspondence: Rahul Banerjee, Division of Medical Oncology, Department of Medicine, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, LG-650, Seattle, WA 98109;Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FLDivision of Medical Oncology, Dana-Farber Cancer Institute, Boston, MAHematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TXDivision of Hematology and Medical Oncology, Cleveland Clinic, Lerner College of Medicine, Case Western Reserve University School of Medicine, Cleveland, OHDivision of Hematology/Oncology, University of Maryland, Baltimore, MDAtrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NCDivision of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MNDivision of Transplantation and Cellular Therapy, University of Miami, Miami, FLDivision of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Medical Center, Westwood, KSDepartment of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FLDivision of Hematology/Oncology, Mayo Clinic, Phoenix, AZClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WADepartment of Pharmacy, Medical University of South Carolina, Charleston, SCDivision of Hematology, Medical College of Wisconsin, Milwaukee, WIClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA; Division of Hematology and Medical Oncology, Cleveland Clinic, Lerner College of Medicine, Case Western Reserve University School of Medicine, Cleveland, OHAtrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NCDivision of Hematology/Oncology, Colorado Blood Cancer Institute, Denver, CODepartment of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FLDivision of Transplant and Cellular Therapy, Roswell Park Comprehensive Cancer Center, Buffalo, NYDivision of Hematology/Oncology, Johns Hopkins University, Baltimore, MDDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope Cancer Center, Duarte, CADivision of Hematology and Medical Oncology, Cleveland Clinic, Lerner College of Medicine, Case Western Reserve University School of Medicine, Cleveland, OHDivision of Hematology/Oncology, University of Maryland, Baltimore, MDDivision of Hematology/Oncology, University of California San Francisco, San Francisco, CADivision of Medical Oncology, Dana-Farber Cancer Institute, Boston, MADepartment of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FLDivision of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Medical Center, Westwood, KSDivision of Transplantation and Cell Therapy, Stanford Cancer Center, Palo Alto, CADivision of Medical Oncology, Dana-Farber Cancer Institute, Boston, MADivision of Hematology/Oncology, Mayo Clinic, Jacksonville, FLDepartment of Lymphoma Myeloma, MD Anderson Cancer Center, Houston, TXDepartment of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FLDivision of Hematology/Oncology, Virginia Commonwealth University, Richmond, VADivision of Hematology and Medical Oncology, Cleveland Clinic, Lerner College of Medicine, Case Western Reserve University School of Medicine, Cleveland, OHDivision of Hematology/Oncology, Columbia Irving Medical Center, New York City, NYDivision of Hematology and Medical Oncology, Mount Sinai Tisch Cancer Center, New York City, NYDivision of Hematology and Medical Oncology, Mount Sinai Tisch Cancer Center, New York City, NYDivision of Hematology/Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UTDivision of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Medical Center, Westwood, KSDivision of Hematology/Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UTDivision of Hematology/Oncology, Mayo Clinic, Rochester, MNDivision of Transplantation and Cell Therapy, Stanford Cancer Center, Palo Alto, CADepartment of Lymphoma Myeloma, MD Anderson Cancer Center, Houston, TXDepartment of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FLDivision of Hematology/Oncology, Mayo Clinic, Rochester, MNDivision of Hematology/Oncology, Mayo Clinic, Rochester, MNDivision of Hematology/Oncology, University of California San Francisco, San Francisco, CAAtrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NCHematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TXClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WADivision of Hematology and Medical Oncology, Mount Sinai Tisch Cancer Center, New York City, NYhttp://www.sciencedirect.com/science/article/pii/S2473952925001715 |
| spellingShingle | Rahul Banerjee Alicia Richards Shonali Midha Aimaz Afrough Faiz Anwer Djordje Atanackovic Shebli Atrash Veronika Bachanova Amer M. Beitinjaneh Evguenia Bhurtel Omar Castaneda Puglianini Saurabh Chhabra Kara I. Cicero James A. Davis Binod Dhakal Danai Dima Christopher J. Ferreri Peter A. Forsberg Ciara L. Freeman Megan M. Herr Tania Jain Murali Janakiram Jack Khouri Mehmet H. Kocoglu Anupama Kumar Yuxin Liu Frederick Locke Joseph P. McGuirk Lekha Mikkilineni Omar Nadeem Ricardo D. Parrondo Oren Pasvolsky Lauren C. Peres Sneha Purvey Shahzad Raza Ran Reshef Shambavi Richard Adriana C. Rossi Douglas W. Sborov Leyla Shune Charlotte B. Wagner Saurabh S. Zanwar Surbhi Sidana Krina K. Patel Doris K. Hansen Shaji K. Kumar Yi Lin Thomas G. Martin Peter M. Voorhees Larry D. Anderson, Jr Andrew J. Cowan Gurbakhash Kaur Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma Blood Advances |
| title | Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma |
| title_full | Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma |
| title_fullStr | Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma |
| title_full_unstemmed | Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma |
| title_short | Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma |
| title_sort | universal driving restrictions beyond 4 weeks appear unnecessary following car t therapy in multiple myeloma |
| url | http://www.sciencedirect.com/science/article/pii/S2473952925001715 |
| work_keys_str_mv | AT rahulbanerjee universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT aliciarichards universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT shonalimidha universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT aimazafrough universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT faizanwer universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT djordjeatanackovic universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT shebliatrash universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT veronikabachanova universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT amermbeitinjaneh universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT evgueniabhurtel universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT omarcastanedapuglianini universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT saurabhchhabra universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT karaicicero universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT jamesadavis universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT binoddhakal universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT danaidima universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT christopherjferreri universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT peteraforsberg universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT ciaralfreeman universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT meganmherr universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT taniajain universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT muralijanakiram universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT jackkhouri universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT mehmethkocoglu universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT anupamakumar universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT yuxinliu universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT fredericklocke universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT josephpmcguirk universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT lekhamikkilineni universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT omarnadeem universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT ricardodparrondo universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT orenpasvolsky universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT laurencperes universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT snehapurvey universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT shahzadraza universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT ranreshef universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT shambavirichard universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT adrianacrossi universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT douglaswsborov universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT leylashune universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT charlottebwagner universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT saurabhszanwar universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT surbhisidana universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT krinakpatel universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT doriskhansen universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT shajikkumar universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT yilin universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT thomasgmartin universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT petermvoorhees universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT larrydandersonjr universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT andrewjcowan universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma AT gurbakhashkaur universaldrivingrestrictionsbeyond4weeksappearunnecessaryfollowingcarttherapyinmultiplemyeloma |